global head of Biogen’s biosimilars unit. “With the increasing numbers of approved biosimilars, we expect increased savings and sustainability for healthcare systems and an increase in ...

The thrust of the alliance is directed straight at central nervous system (CNS) disorders – Biogen's core therapeutic focus – and the initial objective is to understand how different forms of ...

Biogen struggled to consistently generate demand over the last ... as well as under-the-radar businesses like Comfort Systems ...

X-ELIO, a global leader in the renewable energy sector, and the Net Zero Consortium for Buyers (NZCB) have announced the signing of six virtual power purchase agreements (PPAs) for a combined total ...

Biogen receives exclusive rights to commercialize ... Stoke’s initial focus are diseases of the central nervous system and the eye that are caused by a loss of ~50% of normal protein levels ...

Biogen and Stoke Therapeutics have signed a partnership agreement to co-develop and sell Stoke’s experimental treatment for Dravet syndrome, a severe form of epilepsy, outside the U.S., the ...

Global Phase 3 TRANSCEND study will evaluate the efficacy and safety of felzartamab, as compared to placebo, in adults with late AMRAMR is a ...

Harbour BioMed created Élancé Therapeutics to develop bispecific antibody drugs for weight loss. Elsewhere, Geron’s CEO is ...

Leerink Global Healthcare Conference 2025 March 10, 2025 11:20 AM ETCompany ParticipantsAlisha Alaimo - President of ...

Stoke Therapeutics Inc. and Biogen Inc. said Tuesday they are entering a collaboration to develop and commercialize a treatment for Dravet syndrome, a severe form of epilepsy that starts in childhood.

Cambridge, Massachusetts Thursday, March 13, 2025, 10:00 Hrs [IST] ...

March 11, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) – announced the initiation of dosing in the global clinical study, TRANSCEND. The Phase 3 study will evaluate the efficacy and ...